Science

Unprecedented scale

For the last few years, we’ve been working on one of the most ambitious studies in radiology AI.

Our clinical study of Mia – our breakthrough AI platform for breast screening – has been unprecedented in scale and rigour. 

Patient safety

We’re committed to patient safety, so we’re going beyond current regulation requirements when it comes to clinically testing our solutions.

And it’s allowed us to design generalisable AI in a multi-site, multi-hardware and multi-country trial, with more than 275,000 cases from real-world screening populations.

Safe and cost-effective

The evidence is clear – Mia is a clinically safe and cost-effective option that provides double reading quality with a single human reader. Resulting in far more efficiency for radiologists and better outcomes for patients.